BTC Capital Management Inc. Acquires Shares of 5,305 Lantheus Holdings, Inc. (NASDAQ:LNTH)

BTC Capital Management Inc. acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 5,305 shares of the medical equipment provider’s stock, valued at approximately $442,000.

Other hedge funds have also added to or reduced their stakes in the company. National Bank of Canada FI increased its position in Lantheus by 35.7% during the 1st quarter. National Bank of Canada FI now owns 445 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 117 shares during the period. AlphaMark Advisors LLC boosted its holdings in shares of Lantheus by 456.3% during the 1st quarter. AlphaMark Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 365 shares in the last quarter. Coppell Advisory Solutions Corp. bought a new stake in shares of Lantheus during the 4th quarter valued at $48,000. Macquarie Group Ltd. boosted its holdings in shares of Lantheus by 21.7% during the 1st quarter. Macquarie Group Ltd. now owns 605 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 108 shares in the last quarter. Finally, Clearstead Advisors LLC bought a new stake in shares of Lantheus during the 1st quarter valued at $52,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LNTH has been the topic of a number of research reports. Truist Financial restated a “buy” rating and set a $125.00 target price on shares of Lantheus in a report on Friday. StockNews.com initiated coverage on shares of Lantheus in a report on Thursday, August 17th. They set a “buy” rating on the stock. Finally, TheStreet upgraded shares of Lantheus from a “c” rating to a “b-” rating in a report on Wednesday, August 9th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Lantheus currently has an average rating of “Buy” and an average target price of $121.83.

Insiders Place Their Bets

In other Lantheus news, President Paul Blanchfield sold 1,500 shares of the business’s stock in a transaction dated Friday, August 18th. The stock was sold at an average price of $65.19, for a total value of $97,785.00. Following the completion of the transaction, the president now owns 90,475 shares of the company’s stock, valued at approximately $5,898,065.25. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, President Paul Blanchfield sold 1,500 shares of the company’s stock in a transaction dated Friday, August 18th. The shares were sold at an average price of $65.19, for a total transaction of $97,785.00. Following the completion of the sale, the president now owns 90,475 shares of the company’s stock, valued at approximately $5,898,065.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Daniel Niedzwiecki sold 4,297 shares of the company’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $67.93, for a total transaction of $291,895.21. Following the sale, the insider now directly owns 66,295 shares of the company’s stock, valued at approximately $4,503,419.35. The disclosure for this sale can be found here. In the last 90 days, insiders sold 19,315 shares of company stock valued at $1,353,773. 1.50% of the stock is owned by insiders.

Lantheus Stock Performance

Shares of Lantheus stock opened at $64.10 on Tuesday. The stock has a market cap of $4.39 billion, a price-to-earnings ratio of 156.34 and a beta of 0.68. The firm’s 50-day moving average is $73.57 and its 200 day moving average is $81.84. Lantheus Holdings, Inc. has a 1 year low of $47.46 and a 1 year high of $100.85. The company has a debt-to-equity ratio of 1.01, a current ratio of 4.88 and a quick ratio of 4.55.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, August 3rd. The medical equipment provider reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.17. Lantheus had a return on equity of 67.18% and a net margin of 2.97%. The business had revenue of $321.70 million during the quarter, compared to analyst estimates of $306.48 million. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 5.19 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.